Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML

Area of Science:

• Immunotherapy
• Hematologic Malignancies
• Molecular Biology

Background:

• Chimeric antigen receptor (CAR) therapy targeting CD19 has revolutionized acute lymphoblastic leukemia (ALL) treatment.
• Identifying effective and safe CAR targets for acute myeloid leukemia (AML) remains a significant challenge.
• The AML surfaceome requires thorough investigation for suitable CAR targets with minimal off-tumor toxicity.

Purpose of the Study:

• To identify novel cell surface targets for CAR therapy in acute myeloid leukemia (AML).
• To develop a robust strategy for selecting CAR targets with high efficacy and safety profiles in AML.
• To explore combinatorial targeting approaches for overcoming challenges in AML CAR therapy.

Main Methods:

• Integrated analysis of large-scale transcriptomics and proteomics datasets from AML and normal tissues.
• Development of a computational algorithm to identify targets expressed on leukemia stem cells but absent in critical normal cell populations (hematopoietic stem cells, T cells) and vital tissues.
• Design and evaluation of a generalizable combinatorial targeting strategy based on stringent efficacy and safety criteria.

Main Results:

• Initial investigations did not identify single AML surface targets with a safety and efficacy profile comparable to CD19 in ALL.
• A combinatorial targeting strategy was developed, fulfilling rigorous criteria for both effectiveness and systemic safety.
• Several promising target pairings were identified for future development in AML CAR therapy.

Conclusions:

• Direct single-target CAR therapy for AML faces significant hurdles due to target expression profiles.
• Combinatorial targeting offers a viable and promising strategy to enhance the safety and efficacy of CAR therapy for AML.
• Further research into identified target pairings is warranted to advance CAR-based treatments for acute myeloid leukemia.